Filing Details
- Accession Number:
- 0001209191-17-029545
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-03 13:08:42
- Reporting Period:
- 2017-05-02
- Filing Date:
- 2017-05-03
- Accepted Time:
- 2017-05-03 13:08:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1571498 | Epizyme Inc. | EPZM | Pharmaceutical Preparations (2834) | 261349956 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1577021 | A Robert Copeland | C/O Epizyme, Inc. 400 Technology Square Cambridge MA 02139 | President Of Research And Cso | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Commons Stock, Par Value $0.0001 | Acquisiton | 2017-05-02 | 5,000 | $3.54 | 36,538 | No | 4 | M | Direct | |
| Commons Stock, Par Value $0.0001 | Disposition | 2017-05-02 | 5,000 | $17.44 | 31,538 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-05-02 | 5,000 | $0.00 | 5,000 | $3.54 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 38,550 | 2023-01-24 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 per share to $17.65 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- This option is fully vested.
Billionaire Hedge Funds
